Introduction
Type 1 diabetes is caused by autoimmune destruction of pancreatic islet ␤ cells, leading to severe insulin deficiency. Patients are treated with multiple daily insulin injections based on the number and content of meals eaten and the sensitivity of each patient to the biologic effect of the hormone. 1 Glucose control by current insulin replacement therapy is not as precise as by natural insulin secretion, even when a combination of short-, intermediate-and long-acting insulin components is used. Gene therapy of diabetes can be aimed at providing endogenous insulin production to replace these multiple daily injections, and this strategy has been tested in diabetic animal models. [2] [3] [4] Insulin can be expressed and proteolytically processed to its mature form in non-␤ neuroendocrine cells as well as non-neuroendocrine cells. 5, 6 By introducing a furin cleavage site into the B/C and C/A junctions in the proinsulin peptide, insulin can be matured and secreted in a variety of cell types, such as transduced fibroblasts, myoblasts and hepatocytes. [7] [8] [9] [10] Constitutive secretion of insulin by retrovirus-transduced hepatocytes or fibroblasts was sufficient to prevent ketoacidosis in diabetic rats, 2, 3 and to reverse hyperglycemia in diabetic mice. 4 Although the production and maintenance of basal levels of blood insulin can provide hepatoma cells in which expression of the insulin gene was controlled by the G6Pase promoter. While insulin strongly inhibited the G6Pase promoter activity under low glucose conditions, its inhibitory capacity was attenuated when glucose levels were elevated. At the physiologic glucose level of 5.5 mM glucose, vector-transduced hepatoma cells produced a self-limited level of insulin at approximately 0.2-0.3 ng/ml, which is within the range of fasting levels of insulin in normal animals. These results indicate that the G6Pase promoter possesses desirable features and may be developed for regulated hepatic insulin gene expression in type 1 diabetes. Gene Therapy (2000) 7, 1802-1809.
protection against ketoacidosis, 3 there is significant risk of hypoglycemia with unregulated insulin expression. Indeed, most animals implanted with insulin-producing fibroblast cells displayed a considerable drop in blood glucose and subsequently became hypoglycemic. 4 Successful treatment of type 1 diabetes would require the correction of hyperglycemia while avoiding insulininduced hypoglycemia. Thus, production of insulin from non-␤ cells should ideally be induced by hyperglycemia and suppressed by hypoglycemia and hyperinsulinemia.
Glucose-6-phosphatase (G6Pase) catalyzes the hydrolysis of glucose-6-phosphate to glucose, the terminal step in both the gluconeogenic and glycogenolytic pathways. Liver G6Pase activity, which is increased under diabetic conditions, determines the rate of hepatic glucose output. 11 While increased production of glucose helps to maintain fasting euglycemia in normal individuals, excessive production of glucose is the major cause of fasting hyperglycemia in diabetics. 12, 13 Transcription of the G6Pase gene is strongly inhibited by insulin, mediated by a multicomponent insulin-response sequence in the promoter region.
14 Under diabetic conditions, hypoinsulinemia and hyperglycemia contribute to the increased expression of G6Pase. 15, 16 We hypothesize that self-limiting insulin production could be achieved by using the G6Pase gene promoter to drive insulin expression in the liver, and the amount of insulin production could be elevated in the presence of high levels of glucose. Recombinant adenoviral vectors with high transduction efficiency and rat hepatoma cells (H4IIE) were used for studying the insulin and glucose responsiveness of insulin production driven by the G6Pase gene promoter.
Results
Glucose stimulation of G6Pase promoter activity in adenovirus-transduced hepatoma cells The 1.38-kb fragment containing rat G6Pase promoter was cloned by PCR and the fidelity of the promoter sequence was confirmed by DNA sequencing (Figure 1a) . Four E1-deleted adenoviral vectors were constructed (Figure 1b) , in which the reporter gene CAT and the engineered rat insulin cDNA (erINS) were respectively controlled by the rat G6Pase promoter (Ad.G6P-CAT and Ad.G6P-erINS) or by the RSV promoter (Ad.RSV-CAT and Ad. RSV-erINS). The regulation of the G6Pase promoter by glucose and insulin was tested in H4IIE hepatoma cells (ATCC1548-CRL) transduced by CAT-expressing adenoviral vectors (Ad.G6P-CAT and Ad.RSV-CAT) under different glucose and insulin conditions. To compare glucose effects under different insulin conditions, the promoter activity in the presence of 5.5 mm glucose with or without insulin was designated as 100%. The G6Pase promoter activity in hepatoma cells, measured by reporter gene CAT expression, was increased under high glucose conditions in the absence of insulin as well as in the presence of 0.25 ng/ml insulin, which is in the range of normal fasting insulin levels in vivo (approximately 0.2-1 ng/ml). 17 In the absence of insulin, the G6P promoter activities under no-glucose and 27.5 mm glucose conditions were 50.9 ± 10.4% and 178.7 ± 30.2% of that observed in 5.5 mm glucose, respectively. In the presence of 0.25 ng/ml insulin, the G6P promoter activities under no-glucose and 27.5 mm glucose conditions were 6.5 ± 4.8% and 221.6 ± 35.0% of that observed in 5.5 mm glucose, respectively ( Figure 2b) . As a control, expression driven by the constitutive promoter, RSV, remained at similar levels under varying glucose and insulin conditions (Figure 2a) . Glucose-stimulated insulin production by adenovirustransduced hepatoma cells As described above, glucose stimulated G6Pase promoter activity in the presence or absence of insulin. By using the G6Pase promoter to drive insulin gene expression, we reasoned that glucose-dependent insulin production could be achieved in hepatoma cells. To test the level of insulin production in response to glucose, fixed doses of insulin-producing viruses, Ad.RSV-erINS (1 × 10 9 particles) and Ad.G6P-erINS (3 × 10 10 particles), were used to transduce separately H4IIE hepatoma cells (3 × 10 6 ) under different glucose conditions. Insulin levels in the culture media of transduced cells were measured. In the absence of glucose, a very low level of insulin was produced from transduced hepatoma cells in which the G6Pase promoter controlled insulin expression ( Figure 3 ). The insulin levels steadily increased in response to the increasing levels of glucose. The insulin production level in the absence of glucose represented only 30.8 ± 3.7% of that produced under normal glucose conditions (5.5 mm), while insulin production under high glucose conditions (27.5 mm) increased to 168.2 ± 9.2% ( Figure 3 ). In comparison, transduced hepatoma cells in which the constitutive promoter RSV controlled insulin expression produced similar amounts of insulin in the presence of different concentrations of glucose ( Figure 3 ).
Insulin suppression of the G6Pase promoter in adenovirus-transduced hepatoma cells
To compare insulin effects under different glucose conditions, the promoter activities in the absence of insulin 1, 3, 5.5, 8, 11, 16.5, 22 and 27.5 under different glucose conditions were separately designated as 100%. In contrast to the lack of effect of insulin on RSV promoter activity (Figure 4a ), insulin had a strong inhibitory effect on the G6Pase promoter activity in hepatoma cells under different glucose conditions (Figure 4b ). In the absence of glucose, the G6Pase promoter activity was decreased to 3.8 ± 2.8% in the presence of 0.25 ng/ml of insulin compared with its activity in the absence of insulin under the no-glucose condition. However, in the presence of 5.5 mm or 27.5 mm glucose, the G6Pase promoter activities were reduced to 29.5 ± 4.3% or 36.5 ± 5.8%, respectively, compared with the same conditions without insulin (Figure 4b) . Thus, to some extent, the stimulatory effect of high glucose counteracted the inhibitory effect of insulin on G6Pase promoter activity. To determine the relationship between insulin levels and G6Pase promoter activity, the CAT-expressing vectors (Ad.G6P-CAT or Ad.RSV-CAT) at fixed doses were used to transduce hepatoma cells in the presence of different steady-state concentrations of insulin. The various steady-state levels of insulin were achieved by cotransduction of the hepatoma cells with the constitutive insulin-expressing vector (Ad.RSV-erINS) at increasing doses. Insulin levels and CAT activities were measured in the culture media and in the cells, respectively. Under normal glucose condition (5.5 mm), endogenous production of insulin at about 0.1 ng/ml inhibited G6Pase promoter activity by 50% ( Figure 5) . However, the G6Pase promoter could not be completely inhibited even at the highest insulin concentration achieved (3-4 ng/ml). In the presence of 5.5 mm glucose, the G6Pase promoter activity was reduced by 70% when insulin levels in the media reached 0.3 ng/ml. In comparison, the activity of the constitutive promoter RSV remained constant in the presence of different levels of insulin ( Figure 5 ).
mm). Glucose levels in media were monitored by glucometer (Bayer). Insulin in the medium was measured by RIA assay (Linco Research
Self-limited insulin production from adenoviral transduced hepatoma cells Since the G6Pase promoter activity decreased in response to insulin in a dose-dependent manner as described above, insulin production driven by the G6Pase promoter should be self-limiting due to feedback inhibition by insulin. To confirm the self-limiting insulin production, two series of dose-response curves were made: the dose of CAT-expressing vector versus CAT activity and the dose of insulin-expressing vector versus media insulin concentration. As CAT has no biological effect on the promoter activity, the same dose-dependent CAT gene expression should be obtained from both promoters Gene Therapy (G6Pase and RSV). Indeed, a linear relationship between the steady-state CAT activity and viral dose at a proportion ratio of about 1 was observed for both CATexpressing vectors (Ad.G6P-CAT and Ad.RSV-CAT), although the overall G6Pase promoter activity was about 20 times lower than the RSV promoter activity at the same doses (Figure 6a ). For insulin-expressing vectors (Ad.G6P-erINS and Ad.RSV-erINS), however, different patterns of dose-dependent insulin production were observed (Figure 6b ). In the case of the constitutive promoter RSV driving insulin expression (Ad.RSV-erINS) a linear relationship between insulin production and viral dose at a proportion ratio of about 1 was observed, the same as the RSV driving CAT expression. For the insulinsuppressible G6Pase promoter driving insulin production (Ad.G6P-erINS), however, the insulin level did not increase proportionally with the increase in viral dose. Insulin produced from transduced hepatoma cells where insulin expression was controlled by the G6Pase Figure 3, promoter appeared to reach a plateau at approximately 0.2-0.3 ng/ml (Figure 6b ). This level of insulin produced by Ad-G6P-erINS was two to three orders of magnitude lower than that produced by an equivalent dose of Ad.RSV-erINS.
Figure 6 Viral dose-dependent insulin production or CAT activity from adenovirus-transduced hepatoma cells. (a) CAT activity. (b) Insulin production. H4IIE cells (3 × 10

) were transduced by adenoviruses Ad.RSVerINS, Ad.G6P-erINS, Ad.RSV-CAT or Ad.G6P-CAT. Ad.RSV-LacZ virus was used as negative control. Cell culture conditions were similar to those described in
Discussion
The ideal insulin replacement therapy for type 1 diabetes would mimic perfectly the natural insulin secretion in normal individuals. The physiological insulin profile includes rapid postprandial peaks of insulin secretion, followed by relatively low levels of insulin production which are correlated with levels of blood glucose during fasting. Pancreatic ␤ cells achieve this insulin production control via two mechanisms: glucose-stimulated insulin secretion and glucose-stimulated insulin gene expression. This glucose responsiveness requires the presence of two glucose sensing-related proteins: glucose transporter (Glut2) and glucokinase (GK). Insulin can be secreted in response to a physiological range of glucose concentration in mouse pituitary corticotroph-derived cell lines (AtT20), [18] [19] [20] an islet-derived cell line, 21 and insulinoma cell lines. 22, 23 All these cell lines express Glut2 and GK. However, these cell lines are abnormal or tumorgenic and may not be used directly for diabetes treatment. 24 Hepatocytes are non-neuroendocrine cells that naturally express Glut2 and GK, and can be successfully transduced in vitro and in vivo. Therefore, they represent a cell type potentially capable of glucose-regulated insulin expression. Since protein secretion by hepatocyte is constitutive, it will be difficult to achieve an instant release of insulin in sufficient concentrations to deal with high postprandial glucose levels. However, insulin production can be regulated at the level of transcription by using regulatory promoter and control elements. The promoter of PEPCK (phosphoenolpyruvate carboxykinase) is insulin suppressible and has been used to direct insulin expression in order to achieve the feedback control of insulin production. 25, 26 However, its activity is inhibited by glucose, 27 the opposite of what is required to direct insulin expression. The glucose inducible promoter of L-PK (liver-type pyruvate kinase) has been used to achieve insulin production in response to glucose. 9, 28 However, the L-PK promoter is relatively weak and activation of the L-PK promoter requires the presence of both glucose and insulin. 29 The absence of insulin results in inactivation of this promoter under untreated diabetic conditions.
In the current study, the G6Pase gene promoter was used to drive insulin gene expression in transduced hepatoma cells. The glucose responsiveness in all well characterized hepatic promoters, both negatively (PEPCK) and positively (L-PK, G6Pase), appears to require the presence of some glucose metabolites. 27, 30, 31 The glycolytic enzyme glucokinase (GK) has been considered as a key enzyme for the glucose responsiveness of genes. It has been reported that GK is expressed at low levels, or not at all, in hepatoma cells, including H4IIE cells, 32 and therefore glucose responsive genes in hepatoma cells may not respond to glucose. However, glucose-stimulated G6Pase gene expression was observed in FAO hepatoma cells although the amplitude was lower than that in cells overexpressing GK and in hepatocytes in primary culture. 33 In the H4IIE hepatoma cells we used (ATCC:1548-CRL, Batch No: F-12431), GK expression was detected under different glucose conditions (RT-PCR results, data not shown). G6Pase gene promoter activity responded to glucose in this H4IIE cell line in the absence as well as in the presence of insulin. The inhibitory effect of insulin on G6Pase promoter activity was difficult to quantify in insulin-producing cells where the G6Pase promoter controlled insulin production. The insulin inhibitory effect on insulin driving promoters has been assessed either by measuring insulin production with or without phosphatidylinositide 3-kinase inhibitors (eg Wortmannin), which block the insulin receptor-mediated signaling pathway, 34 or by measuring insulin mRNA levels in insulin-expressing cells cultured with/without exogenous insulin. 25, 26 However, blockage of the insulin-signaling pathway may not be complete or sufficient for the repression of G6Pase expression by insulin and may result in unexpected metabolic changes, which may not reflect conditions observed in the absence of insulin. Exogenous insulin added to the culture could not be maintained at the original concentration over time since hepatocytes actively degrade insulin. Of course, the inhibitory effect of exogenously added insulin cannot be distinguished from that of endogenously produced insulin. In the case of the G6Pase promoter, insulin inhibitory effects occur at very low levels of insulin. In our study, a two-virus system, one expressing insulin at different steady-state concentrations and the other expressing a reporter gene (CAT) under the G6Pase promoter control at a fixed viral dose, was used to illustrate clearly the inhibitory effect of endogenous insulin production on the G6Pase promoter activity in the transgene-expressing cells.
Glucose-stimulated and self-limited insulin production was achieved by the G6Pase promoter driven insulin expression in vector-transduced hepatoma cells. The insulin production was shown to be glucose concentration dependent. The insulin levels under no glucose and 27.5 mm glucose conditions were 30% and 170% of that observed in 5.5 mm glucose, respectively. On the other hand, the insulin level did not increase proportionally with the increase in viral dose. At the highest dose we used, the amount of insulin produced by Ad-G6P-erINS was two to three orders of magnitude lower than that produced by Ad.RSV-erINS. Self-limited amounts of insulin at approximately 0.2-0.3 ng/ml were produced in cell culture under normal glucose condition (5.5 mm). Interestingly, this insulin level falls in the low range of normal fasting levels of insulin in vivo (approximately 0.2-1 ng/ml). 17 Owing to the narrow therapeutic window of hepatic insulin expression for the treatment of type 1 diabetes, 3 self-limited insulin production may expand the range of safe and effective doses of insulin-expressing viral vectors.
The dual features of self-limited, as well as glucosestimulated, insulin production may be helpful in developing a system in which insulin production can be set at a certain basal level (normal fasting level) under normal glucose conditions and then increased with increasing levels of glucose. However, by using the G6Pase gene promoter, the current insulin expression levels achieved are low, as the produced insulin feeds back to inhibit the promoter activity strongly. A stronger promoter may be required to obtain sufficient insulin production levels to prevent hyperglycemia under dia-betic conditions. The potent insulin repression on the G6Pase gene promoter is mediated by the negative insulin responsive element and its accessory element. 35 Modification of the negative insulin responsive element may increase the basal level activity of the promoter by attenuating the insulin inhibitory effect. Incorporating enhancers may also result in higher basal level activity of the promoter. However, a promoter that is strongly and promptly inhibited by insulin may be helpful in avoiding hypoglycemia due to overexpression of insulin. Therefore, attenuation of the insulin effect on the promoter may not be the optimal choice. While incorporation of enhancers may be an obvious way to strengthen the promoter, further studies will be required to demonstrate the maintenance of the insulin responsiveness and, especially, the glucose responsiveness of the modified promoter.
Moreover, the amplitude of insulin production in response to glucose in the range of 5.5 mm to 27.5 mm must be increased. Although the G6Pase promoter within the 1.3-kb fragment we cloned responds to glucose, it remains unknown which element mediates this glucose responsiveness. A glucose responsive element (GlRE or ChoRE) has been identified in promoters of the liver-type pyruvate kinase gene (L-PK), the spot 14 (S14) gene, and the glucagon receptor gene. [36] [37] [38] This element contains two E-boxes separated by a few nucleotides. A similar consensus sequence does not exist in the G6Pase gene promoter. Insulin and glucose have synergistic effects on L-PK, S14 activity, but antagonistic effects on G6Pase promoter activity. Lack of similarity between glucose responsive element in G6Pase promoter and other glucose responsive elements suggests that a different mechanism may be involved in glucose-stimulated gene expression. Further studies will be aimed at identifying the specific glucose responsive element in the G6Pase promoter. Synergistic effects may possibly be obtained by modifying and/or incorporating other glucose responsive elements into the G6Pase promoter, as a means to increase the sensitivity and strength of the G6Pase promoter in response to glucose, especially in the normal to high glucose range.
For hepatic gene therapy, hepatocytes can be engineered for glucose-stimulated insulin gene expression. The insulin production controlled at transcriptional level might be problematic if high glucose triggered insulin production with dynamics that are uncoupled to the blood glucose, although the promoter activity is regulated by the auto-regulators, glucose and insulin. To address this issue, rapid turnover mRNA sequences may be incorporated into insulin mRNA in order to achieve rapid turn-off of insulin expression. Moreover, a recent study showed that regulated secretion could be conferred on constitutive secretory cells. 39 Insulin can be engineered in such a way that engineered proinsulin can be retained in the ER system of constitutive secretory cells. After induction by an orally administered small molecule, insulin can be matured and subsequently released in relatively large amounts in a relatively short period of time. 39 A system of glucose-stimulated insulin gene expression combined with drug-induced (ideally this 'drug' would be glucose) insulin secretion would closely mimic pancreatic ␤ cell function.
In summary, we have achieved glucose-stimulated and self-limited insulin production in hepatoma cells. The
Gene Therapy amplitude of glucose induction as well as the strength of promoter activity still needs further improvement. Further research focusing on glucose responsive insulin expression together with the regulated insulin secretion may potentially make hepatic gene therapy a successful treatment for type 1 diabetes in the future.
Materials and methods
Cloning of rat glucose-6-phosphatase gene promoter Genomic DNA was extracted and purified from liver tissue of a Sprague-Dawley rat by QIAamp DNA Tissue Mini Kit (Qiagen, Hilden, Germany). The PCR primers, covering the −1309 to +68 region of G6Pase gene (transcriptional start as +1), were synthesized by Genelink (Hawthorne, NY, USA). Extra sequences recognized by restriction enzymes XbaI and XhoI were added in the primers for convenience of cloning. The primer sequences were sense oligo G6P-5: 5Ј-CCTCTAGA TCCAGTCAACTCCCTACTTC-3Ј, and antisense oligo G6P-3: 5Ј-GCTCGAGTTGGTACCTCAGGAAGCTGCC-3Ј. The 1.38-kb DNA fragment was amplified by PCR using pfu-DNA polymerase (Stratagene, La Jolla, CA, USA), then inserted into pBluescript SK+ vector (Stratagene). The correctness of the clone was confirmed by DNA sequencing. The promoter activity was tested by its ability to drive CAT reporter gene expression in hepatoma cells.
Construction of adenoviral shuttle vectors and production of recombinant adenoviruses
Engineered rat preproinsulin-1 cDNA was generated by PCR mutagenesis previously described by Muzzin et al. 3 The B/C junction of proinsulin was altered from Lys-SerArg-Arg to Arg-Ser-Lys-Arg, which is the consensus sequence recognized and cleaved by furin. Several E1-deleted adenoviral vectors were constructed and the correctness was confirmed by DNA sequencing. All recombinant adenoviruses were rescued according to standard procedure. 40 Ten plaques from each virus rescue were picked and used to infect 293 cells. Virus DNA from the cell lysates was characterized by HindIII digestion pattern, by specific PCR to determine the correctness of the desired gene expression cassette in the virus, and by functional assay for expressed protein. One clone for each virus was chosen for large-scale production. Virus preparations were purified by cesium chloride ultra-centrifugation. The particle titer was determined by spectrophotometer. The infectious unit titer was obtained by plaque assay. All purified viruses were stored at −80°C.
Cell culture 293 Cells were cultured in MEM supplemented with 5% calf serum and penicillin/streptomycin. After transfection, cells were overlaid with MEM containing 5% horse serum, 5% yeast extract, 0.5% agarose, 200 mm glutamine, 0.44% NaHCO 3 and 1x penicillin/streptomycin and incubated at 37°C, 5% CO 2 for 10-14 days. Rat hepatoma cell line H4IIE (ATCC:1548-CRL, Batch No.: F-12431) was purchased from American Type Culture Collection (Manassas, VA, USA). Cells were cultured at 37°C and 5% CO 2 in MEM (Gibco-BRL, Rockville, MD, USA) supplemented with 0.1 mm non-essential amino acids, glutamine, ampicillin, 10% fetal bovine serum and 10% calf serum. In experiments for glucose or hormone regulated gene expression, cells were cultured in DMEM without glucose (Gibco-BRL), supplemented with lactate (10 mm) or with glucose in different concentrations and 10% fetal bovine serum. Before virus infection, the culture medium was completely removed and virus in a total volume of 250 l PBS or serum-free DMEM culture media (Gibco-BRL) was added to each 60-mm dish and incubated at room temperature for 30 min. Then, 3 ml of serum supplemented medium was added and the incubation continued at 37°C and 5% CO 2 for 4-6 h. Then, the transduced cells were cultured in condition media for an additional 18-48 h.
Measurement of insulin, glucose and CAT activity
Immunoreactive insulin in the culture media was measured by sensitive rat insulin RIA kit (Linco Research, St Charles, MO, USA) according to the protocol suggested by the company. Insulin detection limit was 20 pg/ml. Glucose was measured by blood glucose test strips (Glucometer Elite; Bayer Corporation, Elkhart, IN, USA). In the case of glucose concentrations below the detection limit, 20 mg/dl (1.1 mm), samples were measured after concentration. For CAT activity measurement, cell extract was prepared using reporter lysis buffer (Promega, Madison, WI, USA), the lysate protein was quantified by Bio-Rad protein assay (Bio-Rad, Hercules, CA, USA). The cell extract of 150 g protein was used for phase-extraction CAT assay. 41 The butyrylated chloramphenicol was separated from the unmodified form by extraction twice in xylene. The radioactivity was measured by liquid scintillation.
